These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 25323614)
1. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis. Suzman DL; Antonarakis ES Oncology (Williston Park); 2014 Oct; 28(10):880, 882. PubMed ID: 25323614 [No Abstract] [Full Text] [Related]
2. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Armstrong AJ Oncology (Williston Park); 2014 Oct; 28(10):881, 883. PubMed ID: 25323615 [No Abstract] [Full Text] [Related]
3. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Voskoboynik M; Staffurth J; Malik Z; Sweeney C; Chowdhury S Expert Rev Anticancer Ther; 2014 Nov; 14(11):1253-6. PubMed ID: 25353342 [TBL] [Abstract][Full Text] [Related]
4. [Docetaxel for metastatic prostate cancer: early is better]. Gietema JA; Oosting SF Ned Tijdschr Geneeskd; 2016; 160():D215. PubMed ID: 27405569 [TBL] [Abstract][Full Text] [Related]
7. A one-two punch against prostate cancer. Johns Hopkins Med Lett Health After 50; 2014 Mar; 26(1):8. PubMed ID: 24937853 [No Abstract] [Full Text] [Related]
8. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Armstrong AJ; George DJ Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005 [TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348 [TBL] [Abstract][Full Text] [Related]
10. Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy. Barnett CM; Flamiatos JF; Beer TM Anticancer Res; 2011 Mar; 31(3):973-4. PubMed ID: 21498723 [TBL] [Abstract][Full Text] [Related]
12. The association between measures of progression and survival in castrate-metastatic prostate cancer. Scher HI; Warren M; Heller G Clin Cancer Res; 2007 Mar; 13(5):1488-92. PubMed ID: 17332293 [TBL] [Abstract][Full Text] [Related]
13. Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Helley D; Banu E; Bouziane A; Banu A; Scotte F; Fischer AM; Oudard S Eur Urol; 2009 Sep; 56(3):479-84. PubMed ID: 18585841 [TBL] [Abstract][Full Text] [Related]
14. NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. Jilani A; George E; Adler AI Lancet Oncol; 2012 Jun; 13(6):573-4. PubMed ID: 22833888 [No Abstract] [Full Text] [Related]
16. Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post-STAMPEDE world. Thompson AL; Sarmah P; Beresford MJ; Jefferies ER BJU Int; 2017 Dec; 120(6):751-754. PubMed ID: 28834013 [No Abstract] [Full Text] [Related]
17. [Promising on advanced cancer, several new drugs coming]. Widmark A; Karlsson CT Lakartidningen; 2012 Feb 22-28; 109(8):416-9. PubMed ID: 22509668 [No Abstract] [Full Text] [Related]